ClinicalTrials.Veeva

Menu

Effects of Intrauterine Administration of Autologous PBMC on the Endometrial Cells Populations

N

Nadezhda Women's Health Hospital

Status

Enrolling

Conditions

Female Infertility

Treatments

Biological: Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC)

Study type

Interventional

Funder types

Other

Identifiers

NCT05421364
10/12042022

Details and patient eligibility

About

The behaviour of the endometrium during its receptive phase is highly dependent on the endometrial cell type composition. Each cell type has its role in the endometrial preparation for the invading embryo. Alteration in the immune cells dialogue could be the main reason for unsuccessful implantation in certain patients. Immune cell homeostasis is often improved by intrauterine administration of autologous PBMC.

There have been numerous reports on the positive effects of the intrauterine administration of autologous PBMC on the IVF outcomes (embryo implantation and ongoing pregnancy success). However, there is little data on the direct effect of the PBMC administration on the cell composition of the endometrium. This study will focus on the changes in the endometrial cell populations by PBMC treatment that could lead to IVF outcome improvement.

The aim of this project is to analyze the effect of intrauterine administration of autologous PBMC on the endometrial cell populations and on the IVF outcome parameters (implantation and ongoing pregnancy success as IVF outcome variables).

Enrollment

300 estimated patients

Sex

Female

Ages

20 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participating in Assisted Reproduction Treatment
  • Presenting altered endometrial immune profile
  • Having primary infertility
  • Having regular menstrual cycles
  • Embryo transfer of euploid embryos

Exclusion criteria

  • Uterine pathologies
  • Endometrial Bacterial infections
  • Active endometrial inflammation
  • Polycystic ovary syndrome
  • Presence of auto anti-bodies such as anti-TPO, anti-TG, ACA, APA, ANA, and anti-dsDNA
  • Presence of mutations involving the coagulation system such as deficiency of factor XII, Pro C, Pro S
  • Cancer diagnostics
  • Positive HIV, HCV or HBV tests

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

300 participants in 1 patient group

Endometrial cell composition
Experimental group
Description:
The cell composition and their quantities will be compared before and after intrauterine administration of PBMC in the endometrial biopsies.
Treatment:
Biological: Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC)

Trial contacts and locations

2

Loading...

Central trial contact

Rumiana Ganeva, MSc; Georgi Stamenov, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems